[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624847":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":25,"studyPopulation":25,"armGroups":32,"interventions":55,"overallOfficials":25,"centralContacts":25,"locations":25,"responsibleParty":81,"collaborators":25,"id":83,"slug":25,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":25,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":25,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":25,"overallStatus":101,"whyStopped":25,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":25},{"fullName":5,"class":6},"Jiangsu Hansoh Pharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":25,"otherOutcomes":25},[9,13,16,19,22],{"measure":10,"description":11,"timeFrame":12},"RP2D for Combination","To evaluate the potent and tolerated of combination(s) and dosage(s) of HS-10504 based therapy in subjects with EGFR mutation-positive locally advanced or metastatic NSCLC who have experienced disease progression on or after prior treatment, which suitable for a Phase II trial","Through the full duration of this trial, approximately 2 years",{"measure":14,"description":15,"timeFrame":12},"ORR","Investigator evaluated overall response rate, to evaluate the efficacy of each combination",{"measure":17,"description":18,"timeFrame":12},"TEAE","incidence of Investigator evaluated Treatment Emerged Adverse Events, graded per CTCAE V5.0",{"measure":20,"description":21,"timeFrame":12},"TRAE","incidence of Investigator evaluated Treatment Related Adverse Events, graded per CTCAE V5.0",{"measure":23,"description":24,"timeFrame":12},"SAE","incidence of Investigator evaluated Severe Adverse Events, graded per CTCAE V5.0",null,{"allocation":27,"interventionModel":28,"interventionModelDescription":25,"primaryPurpose":29,"observationalModel":25,"timePerspective":25,"maskingInfo":30},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":31,"maskingDescription":25,"whoMasked":25},"NONE",[33,39,43,47,51],{"label":34,"type":35,"description":25,"interventionNames":36},"Cohort 1a","EXPERIMENTAL",[37,38],"Drug: HS-10504","Drug: SHR-A2102",{"label":40,"type":35,"description":25,"interventionNames":41},"Cohort 1b",[37,42],"Drug: SHR-A2009",{"label":44,"type":35,"description":25,"interventionNames":45},"Cohort 1c",[37,46],"Drug: HS-20122",{"label":48,"type":35,"description":25,"interventionNames":49},"Cohort 1d",[37,50],"Drug: HS-20117",{"label":52,"type":35,"description":25,"interventionNames":53},"Cohort 2",[37,54],"Drug: SHR-1826",[56,61,65,69,73,77],{"type":57,"name":58,"description":59,"armGroupLabels":60,"otherNames":25},"DRUG","HS-10504","HS-10504 administered orally every day",[34,40,44,48,52],{"type":57,"name":62,"description":63,"armGroupLabels":64,"otherNames":25},"SHR-A2009","SHR-A2009 administered intravenously",[40],{"type":57,"name":66,"description":67,"armGroupLabels":68,"otherNames":25},"HS-20122","HS-20122 administered intravenously",[44],{"type":57,"name":70,"description":71,"armGroupLabels":72,"otherNames":25},"HS-20117","HS-20117 administered intravenously",[48],{"type":57,"name":74,"description":75,"armGroupLabels":76,"otherNames":25},"SHR-1826","SHR-1826 administered intravenously",[52],{"type":57,"name":78,"description":79,"armGroupLabels":80,"otherNames":25},"SHR-A2102","SHR-A2102 administered intravenously",[34],{"type":82,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100624847",false,"NCT07414953","A Phase Ib Study of HS-10504 Combined Therapy in NSCLC","A Phase Ib Study of the Safety, Efficacy, Pharmacokinetics, and Immunogenicity of HS-10504 Combined Therapy in Advanced Non-small Cell Lung Cancer Patients","Inclusion Criteria:\n\n* Cohort1:participants with EGFR mutation advanced stage NSCLC，disease progression on or after prior treatment；\n* Cohort2:participants with MET position advanced stage NSCLC，disease progression on or after prior treatment；\n* With at least 1 target lesion according to RECIST 1.1.\n* Appropriate organ function\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1 and no deterioration within 2 weeks prior to the first dose.\n* Minimum expected survival longer than 12 weeks\n* Female subjects of childbearing potential are willing to take appropriate contraceptive measures and should not breastfeed from signing the informed consent form (ICF) through 6 months after the last dose; male subjects are willing to use barrier contraception (i.e., condom) from signing the ICF through 6 months after the last dose.\n* Voluntarily participate in this clinical trial, understand the study procedures, and be able to sign written informed consent form.\n\nExclusion Criteria:\n\n* Insufficient wash out duration of prior systemic anticancer therapy\n* Local radiotherapy within 2 weeks prior to first dose of investigational drug\n* Pleural\u002Fabdominal effusion requires clinical intervention\n* Major surgery within 4 weeks prior to first dose of investigational drug\n* History of drugs may prolong QT interval\n* Have any grade ≥ 2 residual toxicity according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) from prior anti-tumor therapy (except alopecia and residual neurotoxicity).\n* Presence of brain metastasis or carcinomatous meningtitis\n* History of other primary malignancies\n* Significant, uncontrolled, or active cardiovascular diseases\n* Severe or poorly controlled diabetes\n* Extremely obesity or emaciation\n* Clinically significant bleeding symptoms or obvious bleeding tendency within 1 month prior to the first dose\n* Severe arteriovenous thrombotic events (e.g., deep venous thrombosis, pulmonary embolism) within 3 months prior to the first dose\n* Severe infection within 4 weeks\n* History of systemic glucocorticoids over 28 days prior to first dose of investigational drug\n* Presence of known active infectious diseases,\n* Presence of hepatic encephalopathy, Hepantorenal Syndrome\n* Presence or history of confirmed or suspected ILD;\n* Prior history of significant neurological or mental disorders, including conditions that interfere with assessment, such as epilepsy, dementia, or major depressive disorder.\n* Past history of severe allergy, or history of hypersensitivity to any active or inactive ingredient of investigational drugs.\n* Presence of any conditions that jeopardize subject safety or interfere with study assessments as judged by the investigator.","ALL","18 Years","75 Years",{"count":93,"type":94},400,"ESTIMATED","INTERVENTIONAL",[97],"PHASE1","This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-10504 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).",[100],"Lung Cancer","NOT_YET_RECRUITING","2026-02-14",{"date":104,"type":105},"2026-02-17","ACTUAL",{"date":107,"type":94},"2026-03-30",{"date":109,"type":94},"2028-11-30",{"name":5,"class":6}]